Table 1. Antibody comparison to nonspecific IgG in SCC13 flank tumors.
| SPY | Avg antibody TBR | IgG TBR | p values‡ | 95% CI |
|---|---|---|---|---|
| Bevacizumab vs IgG |
1.49 (n = 3) |
1.02† |
0.07 |
-0.07458- 1.017 |
| Panitumumab vs IgG |
1.62 (n = 3) |
|
0.11 |
-0.3514- 1.551 |
| Tocilizumab vs IgG |
1.50 (n = 3) |
|
0.20 |
-0.6069- 1.566 |
| PEARL |
|
|
|
|
| Bevacizumab vs IgG |
2.70 (n = 3) |
0.98† |
0.03* |
0.3055- 3.138 |
| Panitumumab vs IgG |
2.66 (n = 3) |
|
0.05* |
-0.08456- 3.447 |
| Tocilizumab vs IgG | 2.75 (n = 3) | 0.10 | -0.8020- 4.337 |
Bevacizumab and panitumumab achieved p values < 0.05 when compared with nonspecific IgG when using the Pearl. All others trended toward statistical significance.
†
Reflects a single set of IgG experiments that was performed
‡
Paired t-tests were calculated using GraphPad Prism software